Abstract
Human papillomavirus (HPV) is one of the most common sexually transmitted infections affecting both men and women worldwide. The development of the prophylactic HPV vaccines is a significant pharmaceutical innovation with potential to reduce HPV-related morbidity. However, barriers to the universal use and acceptability of the HPV vaccines continue to exist in both economically privileged and disadvantaged countries. It may be decades before the impact of preventive vaccines on HPV-related diseases caused by the considerable burden of HPV infections will be seen. Collaborative efforts must continue to promote vaccine implementation.
Copyright © 2013 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adolescent
-
Adult
-
Anus Neoplasms / prevention & control
-
Anus Neoplasms / virology
-
Child
-
Condylomata Acuminata / virology
-
Female
-
Human papillomavirus 16
-
Human papillomavirus 18
-
Humans
-
Male
-
Mass Screening / trends
-
Middle Aged
-
Oropharyngeal Neoplasms / virology
-
Papillomavirus Infections / epidemiology
-
Papillomavirus Infections / prevention & control
-
Papillomavirus Infections / transmission
-
Papillomavirus Vaccines*
-
Practice Guidelines as Topic
-
Risk Factors
-
Sexually Transmitted Diseases
-
Uterine Cervical Dysplasia / virology
-
Uterine Cervical Neoplasms / epidemiology
-
Uterine Cervical Neoplasms / prevention & control
-
Uterine Cervical Neoplasms / virology
-
Vaginal Smears
-
Vulvar Neoplasms / virology
-
Young Adult